KEMP BAILEY CEASE
Pharmacy in Ann Arbor, MI

License number
Michigan 4301045245
Issued Date
Sep 16, 1982
Expiration Date
Jan 31, 2019
Category
Pharmacy
Type
CS - 3
Address
Address
Ann Arbor, MI 48109

Professional information

Kemp B Cease Photo 1

Kemp B Cease, Ann Arbor MI

Specialties:
Oncologist
Address:
1500 E Medical Center Dr, Ann Arbor, MI 48109
Education:
University of North Carolina, School of Medicine - Doctor of Medicine
National Institutes of Health-Clinical Center - Fellowship - Research
Board certifications:
American Board of Internal Medicine Certification in Internal Medicine, American Board of Internal Medicine Sub-certificate in Oncology (Internal Medicine)


Kemp Cease Photo 2

Kemp Cease, Ann Arbor MI

Work:
Ann Arbor Veterans Affairs Medical Center
2215 Fuller Rd, Ann Arbor, MI 48105


Kemp B Cease Photo 3

Dr. Kemp B Cease, Ann Arbor MI - MD (Doctor of Medicine)

Specialties:
Oncology, Medical Oncology
Address:
VA Ann Arbor Medical Center
2215 Fuller Rd, Ann Arbor 48105
(734) 769-7100 (Phone)
Certifications:
Internal Medicine, 1984, Medical Oncology, 2011
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
VA Ann Arbor Medical Center
2215 Fuller Rd, Ann Arbor 48105
ProMedica Herrick Hospital
500 East Pottawatamie St, Tecumseh 49286
Education:
Medical School
University Of North Carolina, Chapel Hill, School Of Medicine
Graduated: 1981
University Of Michigan
Graduated: 1982
Graduated: 1984
National Institute Of Health
Graduated: 1987


Kemp Cease Photo 4

Vectors For Cloning And Modification Of Dna Fragments

US Patent:
5827704, Oct 27, 1998
Filed:
Feb 28, 1996
Appl. No.:
8/608437
Inventors:
Kemp B. Cease - Ann Arbor MI
Cortland J. Lohff - Madison WI
Assignee:
The Regents Of The University Of Michigan - Ann Arbor MI
International Classification:
C12N 1500, C12N 1511
US Classification:
4351723
Abstract:
Plasmid vectors are provided which enable for the modification of double-stranded DNA which has blunt or one-base 3' overhanging termini, to include any desired four-base 5' overhang sequence, in the reading frame of choice. These vectors enable the cloning of blunt double-stranded DNA sequences or double-stranded DNA sequences having a one-base 3' overhang into a unique restriction site by blunt-end ligation or by one-base 3' overhang cohesive cloning such as T-cloning. The vectors may be amplified and subsequently excised, thereby producing modified fragments free of vector sequences.


Kemp Cease Photo 5

Epitope-Targeted Anthrax Vaccine

US Patent:
2011025, Oct 20, 2011
Filed:
Oct 14, 2009
Appl. No.:
13/124167
Inventors:
Kemp B. Cease - Ann Arbor MI, US
Jon Oscherwitz - Ann Arbor MI, US
Assignee:
THE REGENTS OF THE UNIVERSITY OF MICHIGAN - Ann Arbor MI
International Classification:
A61K 39/07, A61P 37/04, A61P 31/04, C07K 19/00
US Classification:
42419711, 530300, 530350, 530317
Abstract:
Anthrax vaccine compositions comprise a segment of a PA toxin protein that stimulates a B cell immune response specific for a defined epitope on the protective antigen of , a pharmaceutical excipient and optionally, one or more other protein segments comprising epitopes that augment the B cell response by stimulating a T cell immune response. The pharmaceutical compositions are useful for vaccinating individuals so as to confer protection from disease caused by including anthrax disease resulting from anthrax spore inhalation.